Finally, a RASopathy is a potential cancer syndrome that may predispose individuals to neoplasia, benign or malignant, within their lifetime, and, as such, the same small-molecular inhibitor that may be used to treat a somatic cancer caused by RAS/MAPK pathway activation, such as a MEK inhibitor, may be considered, with modification, to potentially treat germline phenotypic features of a RASopathy, such as cardiomyopathy, neurocognitive issues, lymphatic disorder, etc. It is understandable that nuisances to the definition exist, especially when one is defining a term that continues to evolve. The gene discussed is MAP2K7; the disease is RASopathy.